Comparison of immunohistological staining with different antibodies to the c-erbB-2 oncoprotein

Applied Immunohistochemistry and Molecular Morphology

Volumn 4, Issue 2, 1996, Pages 128-134

  Bobrow, Lynda G ^a   Happerfield, Lisa C ^a   Millis, Rosemary R ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Breast; c erbb 2; Ductal carcinoma in situ; Immunohistochemistry

Indexed keywords

ARTICLE; BREAST CARCINOMA; CARCINOMA IN SITU; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS;

EID: 0029977118     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Cousseus L, Yang-Fent TL, Chen Y-C LE, Gray A, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-9.
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
3. Lovekin C, Ellis IO, Locker A, et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991;63:439-43.
4. Ramachandra S, Machin L, Ashley S, et al. Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma - a detailed morphological analysis. J Pathol 1990;161: 7-14.
5. Van de Vijver MJ, Peterse JL, Mooi MJ, et al. Neu-protein overexpression in breast cancer: association with comedotype ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239-45.
6. Gullick WJ, Love SB, Wright C, Barnes DM, et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991;63:434-8.
7. Bellamy COC, McDonald C, Salter DM, et al. Noninvasive ductal carcinoma of the breast: the Relevance of histologic categorization. Hum Pathol 1993;24:16-23.
8. Wright C, Nicholson S, Angus B, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992;65:118-21.
9. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-6.
10. de Potter CR, van Daele S, van de Vijver MJ, et al. The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathology 1989;15:351-62.
11. Dawkins HJS, Robbins PD, Sarna M, et al. c-erbB-2 amplification and overexpression in breast cancer: evaluation and comparison of Southern blot, slot blot, ELISA and immunohistochemistry. Pathology 1993;25:124-32.
12. Cuny M, Simony-Lafontaine J, Rouanet P, et al. Quantification of c-erbB-2 protein expression in breast cancer: three levels of expression defined by their clinico-pathological correlations. Oncol Res 1994;6:169-76.
13. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
14. Hynes NE, Gerber HA, Sauser S, Groner B. Overexpression of the c-erbB-2 protein in human breast tumour cell lines. J Cell Biochem 1989;39:167-73.
15. Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994;11:167-80.
16. Bobrow LG, Happerfield LC, Gregory WM, et al. The classification of ductal carcinoma in situ and its association in the biological markers. Semin Diagn Pathol 1994;11:199-207.
17. Norton AJ, Jordan S, Yeomans P. Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Clin Pathol 1994;173:371-9.
18. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-7.
19. Kay EW, Walsh CJB, Cassidy M, Curran B, Leader M. c-erbB-2 immunostaining: problems with interpretation. J Clin Pathol 1994;47:816-22.
20. Venter DJ, Tuzi NL, Kumar S, Gullick WJ. Overexpression of the c-erbB-2 onco-protein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet 1987;2:69-72.
21. Gusterson, BA, Gullick WJ, Venter DJ, et al. Immunological localisation of c-erB-2 in human breast carcinomas. Mol Cell Probes 1988;2:383-91.
22. Hubbard AL, Doris CP, Thompson AM, et al. Critical determination of the frequency of c-erbB-2 amplification in breast cancer. Br J Cancer 1994;70:434-9.